Background: SI is a significant medical problem. DFA-02 is an investigational bioresorbable modified release gel consisting of both gentamicin (16.8 mg/mL) and vancomycin (18.8 mg/mL). A Phase 2a study, where the drug was applied during surgical incision closure, suggested safety and tolerability but was not designed to assess its efficacy.

Study Design: In a Phase 2b randomized, blinded trial patients undergoing abdominal, primarily colorectal, surgery were randomized (4:1:1) to one of three study arms: DFA-02, matching placebo gel, or standard of care (SOC) involving irrigation of the wound with normal saline. The DFA-02 and placebo gel groups received up to 20 mL of study drug inserted above the fascia during wound closure, and were treated in a double-blind manner; the SOC group was treated in a single-blind manner. The primary endpoint was SSI (adjudicated centrally by a blinded committee) through postoperative day 30.

Results: Overall, 445 subjects (intention-to-treat) were randomized at 35 centers with 425 subjects completing the study and being evaluable. There were 67 SSIs (15.8%): 64.2% superficial, 7.5% deep, and 28.4% organ space. The incidence of SSI was not statistically significantly different between the DFA-02 and the placebo gel/SOC arms combined, 42/287 = 14.6% vs 25/138 = 18.1% (p = 0.36), respectively. Rehospitalization within 30 days was also similar between study groups (DFA-02 28.6%, placebo gel 21.4%, SOC 27.3%).

Conclusion: In this multicenter, blinded, randomized trial with central adjudication, the gentamicin/vancomycin gel was not associated with a significant reduction in SSI.

Summary: Patients undergoing abdominal surgery were randomized to one of three study arms: DFA-02 gel consisting of both gentamicin and vancomycin, matching placebo gel, or standard of care (SOC). Of 425 patients completing the study at 35 sites the gentamicin/vancomycin gel was not associated with a significant reduction in SSI.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjsurg.2016.10.007DOI Listing

Publication Analysis

Top Keywords

placebo gel
16
patients undergoing
12
undergoing abdominal
12
gel
9
randomized blinded
8
gentamicin vancomycin
8
abdominal surgery
8
gel consisting
8
consisting gentamicin
8
study drug
8

Similar Publications

Objectives: To evaluate the treatment of peri-implant mucositis (PM) using a nonsurgical submarginal peri-implant instrumentation (NSPI) with or without chlorhexidine (CHX) solutions.

Methods: Fifty-six patients (28 per group) were randomly assigned to the test (NSPI + 0.12% mouthwash and subgingival CHX irrigation plus tongue brushing with 1% CHX gel) or the control group (NSPI + placebo mouthwash and subgingival placebo irrigation plus tongue brushing with placebo gel).

View Article and Find Full Text PDF

Objectives: This randomized controlled clinical trial evaluated the efficacy and safety of peroxide-based mouthrinse on whitening treatment. The patient's satisfaction and treatment longevity were also assessed.

Material And Methods: Participants (N=45) were randomly allocated to three different groups: WM (Whitening mouthrinse - 2.

View Article and Find Full Text PDF

Potentilla fulgens root extract rich in polyphenols ameliorate diabetic foot ulcers in wistar rats via regulating oxidative stress and connective tissue markers.

J Ayurveda Integr Med

January 2025

Girijananda Chowdhury Institute of Pharmaceutical Science (Affiliated to Assam Science and Technology University), Guwahati, 781017, Assam, India; Phytochemical Research Laboratory, School of Pharmaceutical Sciences, Girijananda Chowdhury University, Guwahati, 781017, Assam, India. Electronic address:

Background: Potentilla fulgens (Wall.) ex Hook. (Rosaceae), commonly known as 'Bajradanti' is native to the lower Himalayan regions inclusive of the North-East India.

View Article and Find Full Text PDF

Clinical Applications of Microbiome in Renal Cell Carcinoma.

Eur Urol Focus

January 2025

Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA. Electronic address:

Advancements in microbiome research reveal its impact on cancer treatment outcomes, particularly in renal cell carcinoma (RCC). While immune checkpoint inhibitors (ICIs) have improved survival in metastatic RCC, composition of the gut microbiome has the potential to influence their efficacy. Antibiotic-induced microbiome disruptions correlate with diminished outcomes, while strains such as Akkermansia muciniphila, Clostridium butyricum, and others enhance immune responses and progression-free survival.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!